导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.46% | 1078/4773 |
| 近一周 | -2.68% | 2830/5462 |
| 近一月 | -4.28% | 2352/5421 |
| 近一季 | -5.42% | 1840/5209 |
| 近半年 | -2.82% | 2036/4920 |
| 近一年 | 8.27% | 1207/4366 |
| 近两年 | 75.32% | 873/2954 |
| 近三年 | 46.15% | 605/2253 |
| 成立以来 | 83.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.55% 1507/4961 |
16.15% 1596/5312 |
- - |
- - |
| 2025 | 32.51% 1178/4813 |
3.30% 1124/3635 |
3.11% 1159/4076 |
26.21% 1356/4524 |
-1.43% 2930/4813 |
| 2024 | 9.17% 1489/3463 |
-0.50% 1119/2808 |
-4.02% 1455/3014 |
14.47% 1967/3129 |
-0.13% 1327/3463 |
| 2023 | -5.43% 738/2656 |
6.26% 705/2280 |
-3.78% 895/2385 |
-3.22% 869/2515 |
-4.44% 1035/2655 |
| 2022 | -16.90% 529/2207 |
-10.81% 429/1919 |
3.02% 1230/2016 |
-10.15% 354/2113 |
0.66% 1469/2208 |
| 2021 | 8.08% 486/1822 |
-0.83% 396/1255 |
12.15% 345/1330 |
1.43% 451/1466 |
-4.19% 1471/1822 |
| 2020 | 33.72% 451/1250 |
-3.06% 289/1028 |
21.81% 223/1067 |
9.58% 639/1164 |
3.35% 920/1184 |
| 2019 | 39.99% 262/1092 |
27.40% 349/739 |
-6.75% 519/788 |
8.52% 62/850 |
8.59% 301/918 |
| 2018 | -25.51% 356/834 |
- - |
-9.91% 291/631 |
-5.69% 376/660 |
-11.52% 309/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时中证500指数增强A VS. 长安沪深300非周期A(740101) |